Anti-Mouse CD154 – APC
Anti-Mouse CD154 – APC
Product No.: C2350
Formats AvailableView All
CD40 ligand (CD40L), gp39, T-BAM, TRAP, Ly-62, TNFSF5
Activated mouse Th1 clone D1.6
This Allophycocyanin (APC) conjugate is formulated in 0.01 M phosphate buffered saline (PBS) pH 7.4, 150 mM NaCl, 1% BSA and 0.09% sodium azide as a preservative.
The antibody was purified by affinity chromatography (protein a) and conjugated with APC under optimal conditions
Storage and Handling
This APC conjugate is stable when stored at 2-8°C. Do not freeze.
Country of Origin
Next Day 2-8°C
Red Laser (633 nm)
Applications and Recommended Usage?
Quality Tested by Leinco
FC The suggested concentration for this MR1 antibody for staining cells in flow cytometry is ≤ 0.25 μg per 106 cells in a volume of 100 μl. Titration of the reagent is recommended for optimal performance for each application.
Additional Applications Reported In Literature ?
Note: For most successful immunofluorescent staining results, it may be important to maximize signal over background by using a relatively bright fluorochrome-antibody conjugate or by using a high sensitivity, three-layer staining technique. Therefore, this antibody conjugate may not be suitable for all applications
Each investigator should determine their own optimal working dilution for specific applications. See directions on lot specific datasheets, as information may periodically change.
Clone MR1 recognizes an epitope on mouse CD154.
CD154 is expressed on activated CD4+ T cells.
CD40 is a 48 kD type I transmembrane glycoprotein that is a member of the TNFR superfamily. CD40, in association with its ligand CD154 (CD40L) - a 39 kD protein, acts as a costimulatory molecule for the activation of B cells, dendritic cells, monocytes, and other antigen presenting cells. CD40 is involved in Ig isotype switching and dendritic cell maturation, as well as the activation, differentiation and proliferation of B cells. CD40 interacts with TNFR2 and is involved in the regulation of signal transduction. CD40 is a potential target for cancer immunotherapy. Blocking the interaction of CD40 with its ligand (CD154) is the sought-after therapeutic objective for preventing and/or improving both autoimmune diseases and transplant rejection. Studies have shown that monoclonal antibodies that block CD154 in human clinical trials resulted in unanticipated vascular complications. Hence, an interest in the therapeutic potential for antagonist mAbs specific for human CD40 is emerging. Antibodies of particular therapeutic interest are those that do not inhibit CD40 signaling via physical competition with CD154. Additionally, the interaction of CD40 and its ligand (CD154) is found to be essential for amyloid-beta-induced microglial activation, thus plays a significant part in Alzheimer disease pathogenesis.
T-B cell costimulation
NCBI Gene Bank ID
Products are for research use only. Not for use in diagnostic or therapeutic procedures.